Actualising the power of antibody-drug conjugates as cancer therapeutics
European Pharmaceutical Review
AUGUST 24, 2022
ANTIBODY-DRUG conjugates (ADCs) are therapeutic molecules designed as highly targeted medicines with the promise of changing the way we treat cancer and other diseases. tag ® , inspired by the unique features of microtubule biology and perfectly suited for DAR 2 and DAR 4 ADCs. cancer agent or disease-relevant toxin.
Let's personalize your content